RVPH Live signals | Maximize Profits with Getagraph.com

BUY 105267 min ago

@ $4.65

Issued: 13 Feb 2024 @ 12:23

Return: -35.48%

Previous signal: Feb 13 - 09:32

Previous signal: Sell

Return: 4.26 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 15:50):

Stats
Today's Volume	105 554
Average Volume	296 862
Market Cap	83.76M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $-0.280 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.820
ATR14	$0.0140 (0.47%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-20	Saxena Parag	Buy	585 366	Pre-Funded Warrant
2023-11-20	Saxena Parag	Buy	585 366	Common Stock Warrant (right to buy)
2023-11-13	Funtleyder Leslie D.	Buy	8 200	Stock Option (right to buy)
2023-11-13	Patel Purav	Buy	8 200	Stock Option (right to buy)
2023-11-13	Saxena Parag	Buy	8 200	Stock Option (right to buy)

INSIDER POWER
100.00
Last 72 transactions
Buy: 9 383 157 \| Sell: 2 515 186

Volume Correlation

Long: 0.04 (neutral)

Short: 0.62 (weak)

Signal:(42.823) Neutral

Reviva Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations
ISNS	-0.839
APOP	-0.832

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Reviva Pharmaceuticals Correlation - Currency/Commodity

0.28
( neutral )

0.47
( neutral )

0.00
( neutral )

0.10
( neutral )

0.00
( neutral )

0.27
( neutral )

Reviva Pharmaceuticals Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.250

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.250

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.662

FY	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.240

Financial Reports:

No articles found.

Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.